GLP-1s: A Catalyst, Not a Cure

Why Lasting Health Requires More Than a Prescription

With more than 40% of Americans already living with obesity — and rates projected to rise over the next decade [1] — the need for real support is growing fast.

GLP-1 medications — Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide) — have stepped into the spotlight as a powerful new tool. Their growing popularity is fueling a wave of innovation and investment, leading to new formulations, broader applications, and rising demand. Already this year, three more GLP-1-based drugs are advancing through the FDA’s review process [2].

These drugs promise what so many have long struggled to find: a quieter appetite, fewer cravings, and meaningful weight loss. But as more people seek them out, a harder truth is beginning to surface: while they may spark change, results can fade, side effects can add up, and the deeper work of health often gets left behind.

So before we call this a cure, it’s worth asking: what happens when the prescription runs out? And what’s missing from the conversation in between?

Behind the Hype

GLP-1 medications are widely seen as a miracle drug. Nearly 12% of U.S. adults report using one [3], and projections suggest that GLP-1 households may drive 35% of all food and beverage sales by 2030 [4]. Their rapid rise speaks to how deeply people want change — but it often overshadows the full picture of what these drugs can (and can’t) do.

Beneath the enthusiasm, the reality is more complex.

Nausea and vomiting are common among users, and may stem from more than reduced appetite alone, potentially involving brain pathways that regulate these symptoms [5]. Hundreds have reported cases of acute pancreatitis, prompting increased scrutiny from regulators and clinicians [6]. Emerging research has also raised questions about potential associations with issues like chronic cough [7]. Cost is another concern: half of users say the drugs are difficult to afford [8].

That toll is reflected in the data: nearly half of users discontinue GLP-1 therapy within a year [9, 10]. The most commonly reported reason is side effects, cited in 28.2% of cases — frequently involving gastrointestinal symptoms, including nausea and vomiting, as well as diarrhea and constipation, which many, particularly older adults, find difficult to tolerate [10].

Taken together, these drawbacks challenge the idea that GLP-1s offer a frictionless fix. They may dull hunger, but they do so at a physiological and financial cost — and often without lasting support.

The Limits of Suppression

Even when GLP-1s lead to reduced appetite and meaningful weight loss, the effect is often short-lived — not just because it depends on continued use, but because what seems like control at first can begin to slip, revealing how little has changed beneath the surface.

While these drugs can muffle urges to eat — what researchers call “food noise” — that silence doesn’t always last. In limited early evidence, brain activity linked to food preoccupation has been observed to return within months, even during ongoing treatment [11, 12]. These medications don’t fundamentally rewire the systems that govern the feeding drive. They interrupt. They don’t transform.

This helps explain why many users regain weight once the drug is stopped [9]. According to Oxford researchers, people who discontinued the medication gain an average of nearly 1 pound (0.4 kilograms) per month post-treatment — a faster rebound than what’s observed in behavioral programs. Cardiometabolic improvements like lower blood pressure and cholesterol levels also tend to reverse within 1.4 years [9].

Behavioral patterns follow a similar arc. A Cornell study tracking 150,000 U.S. households found that within six months of starting GLP-1s, grocery spending dropped by 5.3%, especially in categories like cookies, chips, and sweets [13]. Fast food purchases declined as well. But once participants stopped taking the drug, their shopping habits reverted — and in some cases, became less healthy than before, with increased spending on candy and chocolate [13].

The takeaway? When support is temporary but the patterns run deep, hunger returns — and it leads right back to where you started.

Beyond the Spark

GLP-1 medications can play an important role — especially for those facing urgent health risks or long-standing struggles with weight. For many, they offer a crucial psychological reset that helps interrupt cycles of frustration. Weight loss can also bring physical relief, like lower blood pressure and less joint pain. They can create momentum.

But that momentum is fragile. Without guidance, it fades.

What’s often missing isn’t more medication — it’s education. Most people taking GLP-1s are never taught how to eat when their cravings are quieted, or how to navigate food once their appetite returns. There’s no roadmap for transitioning off the drug. No structured path for rebuilding food skills.

A 2026 review from the University of Cambridge found that most GLP-1 users in the UK receive little to no nutritional support — despite 95% accessing these medications privately [14]. Even in well-resourced settings, basic guidance is still missing. The authors were clear: without structured nutrition care, patients face “preventable nutritional deficiencies and largely avoidable loss of muscle mass” [14].

The World Health Organization has echoed this concern. In its first global guideline on GLP-1 therapies for obesity, WHO emphasized that these medications should be prescribed alongside behavioral strategies focused on a healthy diet and physical activity [15].

These drugs may act as the catalyst — but without insight, there’s nothing to keep the fire going. Because the challenge isn’t simply biological. It’s that we continue to separate treatment from teaching — appetite suppression from nutrition literacy. We intervene without empowering. And in doing so, we squander the chance to turn that early momentum into real, durable progress.

GLP-1s may initiate change — but healing happens beyond it, through skill, understanding, and a renewed connection to food.

Choosing With Care

GLP-1s can reduce weight — but lighter doesn’t always mean healthier, especially when progress comes with side effects, nutritional gaps, or no foundation for lasting success. Weight loss alone doesn’t build metabolic resilience, restore nourishment, or establish the daily practices that protect long-term health.

So how do you approach this therapy wisely — understanding both what it offers now and what it asks of you later?

Before you begin, be clear on what’s ahead: the likely duration, the financial cost, the physical impact. Is this something your body — and your life — can realistically sustain?

Then look ahead. If the medication helps you make progress, what happens next? Do you have a plan to keep building — to strengthen your food skills, nurture your biology, and shift from suppression to self-directed care?

That might mean working with a registered dietitian, exploring evidence-based strategies to build better habits, and developing a clear plan for transitioning off the medication — one that helps you stay nourished, confident, and supported long after the treatment ends.

Because the goal isn’t just to lose weight. It’s to build health that lasts — with AND without a prescription.

Ending the Cycle

As obesity rates continue to rise, the need for meaningful solutions has never been more urgent. GLP-1 medications can be part of that support — especially for those navigating serious health concerns. They can offer relief, momentum, and a way forward.

But no medication can do it alone.

Our challenges go beyond appetite. They include access to education, consistent guidance, and a food system where healthy choices are realistic, not rare.

If we want outcomes that last, we have to look at the bigger picture: real change comes from learning how to eat and making sure everyone has the tools and knowledge to do it with confidence. That’s where progress begins. And that’s where the cycle of confusion, restriction, and relapse can finally break.

Disclaimer

This article is for educational purposes only and is not medical advice. Talk with a qualified clinician about what’s appropriate for you.

References

1. DeCleene, N. K., E. Kahn, C. W. Yuan, E. Gakidou, A. H. Mokdad, C. J. L. Murray, C. O. Johnson, and G. A. Roth. “US State-Level Prevalence of Adult Obesity by Race and Ethnicity From 1990 to 2022 and Forecasted to 2035.” JAMA. Advance online publication, 2026. https://doi.org/10.1001/jama.2025.26817. https://pubmed.ncbi.nlm.nih.gov/41604179/
2. Rubin, R. “Data on 3 New GLP-1 Drugs for Weight Loss That May Be Approved This Year.” JAMA. Advance online publication, 2026. https://doi.org/10.1001/jama.2026.0287. https://pubmed.ncbi.nlm.nih.gov/41615674/
3. RAND Corporation. “Nearly 12 Percent of Americans Have Used GLP-1 Weight-Loss Drugs; Medications Are Most Used by Women Aged 50 to 64.” August 6, 2025. Accessed January 30, 2026. https://www.rand.org/news/press/2025/08/nearly-12-percent-of-americans-have-used-glp-1-weight.html.
4. Zimmerman, Sarah. “GLP-1 Users to Make Up 35% of Food and Beverage Sales by 2030: Report.” Food Dive, November 25, 2025. Accessed January 30, 2026. https://www.fooddive.com/news/glp1s-weight-loss-food-beverage-sales-2030/806415/.
5. “How to Keep Ozempic/Wegovy Weight Loss Without the Nausea.” ScienceDaily, November 18, 2025. Accessed January 30, 2026. https://www.sciencedaily.com/releases/2025/11/251118220041.htm.
6. Bawden, Anna. “Hundreds of Weight-Loss and Diabetes Jab Users Report Pancreas Problems.” The Guardian, June 25, 2025. Accessed January 30, 2026. https://www.theguardian.com/society/2025/jun/26/weight-loss-diabetes-jab-users-report-pancreas-problems.
7. Gallagher, T. J., D. E. Razura, A. Li, I. Kim, N. Vukkadala, and A. M. Barbu. “Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough.” JAMA Otolaryngology–Head & Neck Surgery. Advance online publication, 2025. https://doi.org/10.1001/jamaoto.2025.4181. https://pubmed.ncbi.nlm.nih.gov/41296333/
8. KFF. “Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford.” November 14, 2025. Accessed January 30, 2026. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/.
9. West, S., J. Scragg, P. Aveyard, J. L. Oke, L. Willis, S. J. P. Haffner, H. Knight, D. Wang, S. Morrow, L. Heath, S. A. Jebb, and D. A. Koutoukidis. “Weight Regain after Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis.” BMJ (Clinical Research Ed.) 392 (2026): e085304. https://doi.org/10.1136/bmj-2025-085304. https://pubmed.ncbi.nlm.nih.gov/41500720/; https://www.bmj.com/content/392/bmj-2025-085304
10. Truveta Research Team. “Real‑World Temporal and Indication‑Specific Variation in Drivers of GLP‑1 Receptor Agonist Discontinuation.” Truveta Research Blog / ISPOR 2025 Real‑World Evidence Presentation, May 14, 2025. Accessed January 30, 2026. https://www.truveta.com/blog/research/ispor-2025-real-world-temporal-and-indication-specific-variation-in-drivers-of-glp-1-ra-discontinuation
11. Penn Medicine. “Tirzepatide May Only Temporarily Suppress Brain Activity Involved in ‘Food Noise.’” November 17, 2025. Accessed January 30, 2026. https://www.pennmedicine.org/news/tirzepatide-may-only-temporarily-quiet-food-noise.
12. Choi, W., Y. H. Nho, L. Qiu, et al. “Brain Activity Associated with Breakthrough Food Preoccupation in an Individual on Tirzepatide.” Nature Medicine (2025). https://doi.org/10.1038/s41591-025-04035-5. https://www.nature.com/articles/s41591-025-04035-5.
13. Hristakeva, S., J. Liaukonytė, and L. Feler. “EXPRESS: The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand.” Journal of Marketing Research 0(ja), 2025. Accessed January 30, 2026. https://doi.org/10.1177/00222437251412834
14. University of Cambridge. “Experts Sound Alarm Over Nutritional Gaps in People Taking Ozempic and Wegovy.” SciTechDaily, January 15, 2026. Accessed January 30, 2026. https://scitechdaily.com/experts-sound-alarm-over-nutritional-gaps-in-people-taking-ozempic-and-wegovy/; (Spreckley, M., Ruggiero, C. F., & Brown, A. (2026). Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, e70079. Advance online publication. https://doi.org/10.1111/obr.70079)
15. Celletti, F., J. Farrar, and L. De Regil. “World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.” JAMA. Advance online publication, 2025. https://doi.org/10.1001/jama.2025.24288. https://pubmed.ncbi.nlm.nih.gov/41324410/